Journal ArticleDOI
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
Michael P. Manns,John G. McHutchison,Stuart C. Gordon,Vinod K. Rustgi,Mitchell L. Shiffman,Robert Reindollar,Zachary Goodman,Kenneth Koury,Mei Hsiu Ling,Janice K. Albrecht +9 more
Reads0
Chats0
TLDR
In patients with chronic hepatitis C, the most effective therapy is the combination of peginterferon alfa-2b 1.5 microg/kg per week plus ribavirin, and this randomised trial found that the benefit is mostly achieved in patients with HCV genotype 1 infections.About:
This article is published in The Lancet.The article was published on 2001-09-22. It has received 6228 citations till now. The article focuses on the topics: Ribavirin & Peginterferon alfa-2b.read more
Citations
More filters
Journal ArticleDOI
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Michael W. Fried,Mitchell L. Shiffman,K. Rajender Reddy,C. Smith,George Marinos,Fernando L. Gonçales,Dieter Häussinger,Moisés Diago,Giampiero Carosi,Daniel Dhumeaux,Antonio Craxì,A. Lin,Joseph Hoffman,Jian Yu +13 more
TL;DR: In patients with chronic hepatitis C, once-weekly peginterferon alfa-2a plus ribavirin was tolerated as well as interferonAlfa- 2b plus Ribavirin and produced significant improvements in the rate of sustained virologic response, as compared with interfer on alfa -2b plus ribvirin or pegin terferonalfa-3a alone.
Journal ArticleDOI
Management of hepatocellular carcinoma.
Jordi Bruix,Morris Sherman +1 more
TL;DR: The prevention of Cirrhosis can prevent the development of HCC and progression from chronic HCV infection to advanced fibrosis or cirrhosis may be prevented in 40% of patients who are sustained responders to new antiviral strategies, such as pegylated interferon and ribavirin.
Journal ArticleDOI
Effect of pegylation on pharmaceuticals
J. Milton Harris,Robert B. Chess +1 more
TL;DR: How PEGylation can result in drugs that are often more effective and safer, and which show improved patient convenience and compliance are reviewed.
Journal ArticleDOI
Diagnosis, management, and treatment of hepatitis C: An update
TL;DR: This document has been approved by the AASLD, the Infectious Diseases Society of America, and the American College of Gastroenterology.
Journal ArticleDOI
Hepatitis C Virus Infection
Georg M. Lauer,Bruce D. Walker +1 more
TL;DR: The institution of blood-screening measures in developed countries has decreased the risk of transfusion-associated hepatitis to a negligible level, but new cases continue to occur mainly as a result of injection-drug use and, to a lesser degree, through other means of percutaneous or mucous-membrane exposure.
References
More filters
Journal ArticleDOI
Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C
John G. McHutchison,Stuart C. Gordon,Eugene R. Schiff,Mitchell L. Shiffman,William M. Lee,Vinod K. Rustgi,Zachary Goodman,Mei Hsiu Ling,Susannah Cort,Janice K. Albrecht +9 more
TL;DR: In patients with chronic hepatitis C, initial therapy withinterferon and ribavirin was more effective than treatment with interferon alone.
Journal ArticleDOI
Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis
Robert G. Knodell,Kamal G. Ishak,William C. Black,Thomas S. Chen,Robert M. Craig,Neil Kaplowitz,T Kiernan,Jerome Wollman +7 more
TL;DR: A Histology Activity Index has been developed which generates a numerical score for liver biopsy specimens obtained from patients with asymptomatic chronic active hepatitis that provides definitive endpoints for statistical analysis of serial changes in liver histology and offers an alternative to the use of conventional pathological descriptions.
Journal ArticleDOI
The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994
Miriam J. Alter,Deanna Kruszon-Moran,Omana V. Nainan,Geraldine M. McQuillan,Fengxiang Gao,Linda A. Moyer,Richard A. Kaslow,Harold S. Margolis +7 more
TL;DR: The strongest factors independently associated with HCV infection were illegal drug use and high-risk sexual behavior, and poverty, having had 12 or fewer years of education, and having been divorced or separated were independently associated.
Journal ArticleDOI
Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)
Thierry Poynard,Patrick Marcellin,Samuel S. Lee,Christian Niederau,Gerald S. Minuk,Gaetano Ideo,Vincent G. Bain,Jenny Heathcote,Stefan Zeuzem,Christian Trepo,Janice K. Albrecht +10 more
TL;DR: AnInterferon α2b plus ribavirin combination is more effective than 48 weeks of interferonα2b monotherapy and has an acceptable safety profile and patients with few favourable factors benefit more from extending the duration of combination therapy to 48 weeks.
Journal ArticleDOI
Peginterferon alfa-2a in patients with chronic hepatitis C.
Stefan Zeuzem,S.V. Feinman,Jens Rasenack,E.J. Heathcote,M.-Y. Lai,Edward Gane,John O'Grady,J Reichen,Moisés Diago,A. Lin,Joseph Hoffman,M.J. Brunda +11 more
TL;DR: In patients with chronic hepatitis C, a regimen of peginterferon alfa-2a given once weekly is more effective than a regimen that has sustained absorption, a slower rate of clearance, and a longer half-life than unmodified interferonAlfa- 2a.